CBS 2019
CBSMD教育中心
English

急性冠脉综合征

科研文章

荐读文献

Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Myocardial Infarction in Young Women TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial): An Observational Study to Identify Acute Heart Failure Patients at Low Risk for Rehospitalization or Mortality Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction: A Post Hoc Analysis of the Randomized TOTAL Trial Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review
|<<... 23 24 25 26 27 28 29 30 >>|

Editorial2019 Jan 15;139(3):347-350.

JOURNAL：Circulation. Article Link

Percutaneous Support Devices for Percutaneous Coronary Intervention

Patel MR. Keywords: drug-eluting stents; STEMI without cardiogenic shock ; myocardial reperfusion; percutaneous coronary intervention; percutaneous support devices

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top